News related to Pulmicort Respules (Budesonide) and/or conditions it is approved for
Teva Announces Agreement On Generic Pulmicort Respules(R) Patent Challenge
Source: Litigation / Medical Malpractice News From Medical News Today [2008.11.27]
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., has signed an agreement with AstraZeneca to settle patent litigation involving Teva's U.S. generic version of AstraZeneca's Pulmicort (Budesonide) Respules® including all claims for patent infringement and damages. Teva launched its generic budesonide respules in the U.S. on November 18, 2008. The agreement releases Teva for all past U.S.
|
